Pfizer-BioNTech COVID-19 Vaccine Tolerance in Allergic versus Non-Allergic Individuals.
Pfizer-BioNTech COVID-19 Vaccine Tolerance in Allergic versus Non-Allergic Individuals.
复制标题
DOI：
10.3390/vaccines9060553
复制
发表时间：
2021-05-25
期刊：
影响因子：
7.8
通讯作者：
Szenborn L
中科院分区：
文献类型：
--
作者：
Nittner-Marszalska M;Rosiek-Biegus M;Kopeć A;Pawłowicz R;Kosińska M;Łata A;Szenborn L
有过敏史的个人在接种 COVID-19 疫苗后可能面临遭受不良反应的风险。我们试图评估过敏患者对辉瑞 BioNTech 疫苗的耐受性。为了解决这个问题，我们对一组接种了辉瑞 BioNTech 疫苗的医疗专业人员进行了在线调查。共有 1808 名受访者返回了调查问卷，其中 1707 人接种了两剂疫苗。两种剂量后过敏个体注射后的局部反应更为频繁（肿胀 p = 0.0003）。两组中第二次给药后的全身不良事件（AE-SYS）发生率均高于第一次给药（过敏者：77.29% vs. 41.06%）；过敏受试者更常出现呕吐和关节痛 (p = 0.0009)。在第一剂 (p = 0.01) 和第二剂 (p = 0.0009) 后，过敏个体中的 AE-SYS 持续时间比非过敏个体更长。过敏受试者中更频繁地报告疫苗接种后的过敏反应：第一剂接种后 (p = 0.00001) 和第二剂接种后 (p = 0.001)。鼻炎是过敏患者中最常见的症状。整个疫苗接种周期内未发生严重过敏反应。尽管过敏者对辉瑞 BioNTech 疫苗的耐受性比非过敏者差，但出现的不良症状很轻微，并不妨碍成功完成疫苗接种周期。提示过敏的症状的存在并不构成辉瑞 (Pfizer) COVID-19 疫苗接种后发生临床显着不良事件的风险增加的情况。
Individuals with a history of allergy are potentially at risk of suffering from adverse effects after COVID-19 vaccination. We sought to assess the tolerance towards the Pfizer-BioNTech vaccine in allergic patients. To address this issue, we used a questionnaire conducted on-line in a group of medical professionals who were vaccinated with the Pfizer-BioNTech vaccine. A total of 1808 respondents, out of whom 1707 received two doses of the vaccine, returned the questionnaire. Local reactions after injection were more frequent in allergic individuals after both doses (swelling p = 0.0003). Systemic adverse events (AE-SYS) occurred more often after the second than the first dose in both groups (allergic persons: 77.29% vs. 41.06%); vomiting and arthralgia occurred more often in allergic subjects (p = 0.0009). AE-SYS in allergic individuals lasted longer than in non-allergic ones after the first (p = 0.01) and the second dose (p = 0.0009). Allergic reactions after vaccination were reported more frequently in allergic subjects: after the first dose (p = 0.00001) and after the second dose (p = 0.001). Rhinitis was the most frequent symptom observed more often in allergic patients. No severe allergic reactions occurred during the full cycle of vaccination. Although the Pfizer-BioNTech vaccine is tolerated worse by allergic than non-allergic individuals, the occurring adverse symptoms are mild and do not preclude a successful completion of the vaccination cycle. The presence of symptoms suggestive of allergy does not constitute a condition of increased risk of developing clinically significant adverse events following Pfizer COVID-19 vaccination.
登录
查看更多内容
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
--
作者：
Klimek L;Novak N;Hamelmann E;Werfel T;Wagenmann M;Taube C;Bauer A;Merk H;Rabe U;Jung K;Schlenter W;Ring J;Chaker A;Wehrmann W;Becker S;Mülleneisen N;Nemat K;Czech W;Wrede H;Brehler R;Fuchs T;Jakob T;Ankermann T;Schmidt SM;Gerstlauer M;Vogelberg C;Zuberbier T;Hartmann K;Worm M
通讯作者：
Worm M
DOI：
10.1001/jama.2021.1967
发表时间：
2021-03-16
期刊：
JAMA
影响因子：
--
作者：
Shimabukuro TT;Cole M;Su JR
通讯作者：
Su JR
DOI：
10.1016/j.anai.2021.01.017
发表时间：
2021-04
期刊：
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
影响因子：
--
作者：
Murphy KR;Patel NC;Ein D;Hudelson M;Kodoth S;Marshall GD Jr;Parikh P;Blaiss MS
通讯作者：
Blaiss MS
影响因子：
0.2
作者：
Kruszewski, Jerzy;Cichocka-Jarosz, Ewa;Zajdel-Calkowska, Justyna
通讯作者：
Zajdel-Calkowska, Justyna